One Year Duration of Immune Response Following a 3rd Booster Dose of MRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Dec 23

PMID 39711119

Authors

Ondrej Susol

Barbora Susolova

Ondrej Klempir

Milan Navratil

Jaromir Gumulec

Zdenek Koristek

Juraj Duras

Michal Kascak

Jana Mihalyova

Lukas Stejskal

Tomas Jelinek

Petra Richterova

Lenka Szeligova

Hana Plonkova

Jana Zuchnicka

Barbora Dluhosova

Ivo Demel

David Buffa

Katarina Hradska

Tereza Popkova

Ludmila Muronova

Martin Lachnit

Klara Lancova

Roman Hajek

Affiliations

Soon will be listed here.

Abstract

Aims: To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long-term antibody durability in hematological patients.

Materials And Methods: We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12-month follow-up period in our center in Ostrava, Czech Republic.

Results: Antibody response for the whole cohort exceeded 74% through the whole 12-month follow-up. Lowest seroconversion was observed in CLL cohort (20/41, 48.8%), patients who received anti-CD20 therapy < 6 months before vaccination (8/30, 26.7%) and BTK inhibitors (3/6, 50.0%). On the contrary, patients with chronic myeloproliferative neoplasms and acute leukemia performed comparably with healthy population (33/33; 100% and 12/13; 92.3%, respectively). We have seen better results if the time interval between anti-CD20 therapy and additional vaccine dose was longer than 6 months (5/8 patients achieved seroconversion on 4th booster dose after previous failure). Also, 36 patients received a 4th dose of vaccine as a booster with measurable increase in protective antibodies in 50% (18/36).

Conclusions: Additional doses show promise for a well-timed revaccination even in poor responders. To our knowledge, no study comparable to our work in terms of follow-up length, vaccine consistency or variety of hematological malignancies and/or treatment has been reported yet. Our findings shed more light on long-term antibody response to mRNA vaccines against SARS-CoV-2 in patients with hematological cancer and bring important data for the evaluation of possible vaccine failure and scheduling of subsequent doses.

References

Perry C, Luttwak E, Balaban R, Shefer G, Morales M, Aharon A . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021; 5(16):3053-3061. PMC: 8362658. DOI: 10.1182/bloodadvances.2021005094. View

Shen Y, Freeman J, Holland J, Naidu K, Solterbeck A, Van Bilsen N . Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood. 2022; 140(25):2709-2721. PMC: 9550283. DOI: 10.1182/blood.2022017814. View

Saito M, Mori A, Ishio T, Kobayashi M, Tsukamoto S, Kajikawa S . Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study. Viruses. 2024; 16(3). PMC: 10974858. DOI: 10.3390/v16030328. View

Rubin L, Levin M, Ljungman P, Davies E, Avery R, Tomblyn M . 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013; 58(3):e44-100. DOI: 10.1093/cid/cit684. View

Saade C, Gonzalez C, Bal A, Valette M, Saker K, Lina B . Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerg Microbes Infect. 2021; 10(1):1499-1502. PMC: 8330769. DOI: 10.1080/22221751.2021.1945423. View

Simanek V, Pecen L, Kratka Z, Furst T, rezackova H, Topolcan O . Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test. Diagnostics (Basel). 2021; 11(4). PMC: 8065578. DOI: 10.3390/diagnostics11040593. View

Blumenthal K, Phadke N, Bates D . Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink. JAMA. 2021; 326(14):1375-1377. DOI: 10.1001/jama.2021.14808. View

Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N . Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica. 2021; 107(3):625-634. PMC: 8883569. DOI: 10.3324/haematol.2021.279196. View

Tartof S, Slezak J, Puzniak L, Hong V, Frankland T, Ackerson B . Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. Lancet Reg Health Am. 2022; 9:100198. PMC: 8841530. DOI: 10.1016/j.lana.2022.100198. View

10.

Mai A, Lee A, Tay R, Shapiro L, Thakkar A, Halmos B . Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022; 172:65-75. PMC: 9163022. DOI: 10.1016/j.ejca.2022.05.029. View

11.

Rotterdam J, Thiaucourt M, Weiss C, Schwaab J, Reiter A, Kreil S . Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. Ann Hematol. 2022; 101(8):1825-1834. PMC: 9124009. DOI: 10.1007/s00277-022-04866-z. View

12.

Braitsch K, Jeske S, Stroh J, Hefter M, Platen L, Bachmann Q . Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response. Vaccines (Basel). 2024; 12(8). PMC: 11359694. DOI: 10.3390/vaccines12080871. View

13.

Cook L, ODell G, Vourvou E, Palanicawandar R, Marks S, Milojkovic D . Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies. Nat Commun. 2022; 13(1):6922. PMC: 9662771. DOI: 10.1038/s41467-022-34657-z. View

14.

Wirth S, Podar K, Pecherstorfer M, Wohlfarth P, Jaeger U, Singer J . Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study. Cancers (Basel). 2023; 15(2). PMC: 9856293. DOI: 10.3390/cancers15020524. View

15.

Della Pia A, Kim G, Ip A, Ahn J, Liu Y, Kats S . Anti-spike antibody response to the COVID vaccine in lymphoma patients. PLoS One. 2022; 17(12):e0266584. PMC: 9714943. DOI: 10.1371/journal.pone.0266584. View

16.

Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvade V . Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncol. 2022; 8(5):e220446. PMC: 8914885. DOI: 10.1001/jamaoncol.2022.0446. View

17.

Mancuso K, Zamagni E, Solli V, Gabrielli L, Leone M, Pantani L . Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma. Front Oncol. 2023; 13:1208741. PMC: 10249866. DOI: 10.3389/fonc.2023.1208741. View

18.

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

19.

Wendel S, Kutner J, Machado R, Fontao-Wendel R, Bub C, Fachini R . Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Transfusion. 2020; 60(12):2938-2951. PMC: 7756544. DOI: 10.1111/trf.16065. View

20.

Lim Y, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T . Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol. 2024; 205(2):440-451. DOI: 10.1111/bjh.19562. View